A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

Clinical trial NCT04419623 · COMPLETED

Trial details

NCT number: NCT04419623
Sponsor: Telios Pharma, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

COVID-19 Sars-CoV2 Cancer Solid Tumor Carcinoma Blood Cancer

Start date: 2020-07-09
Primary completion: 2020-09-22
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.